Revolutionizing TB treatment: Breakthrough antibiotics for a healthier future A comprehensive review

Kamatam Meghana 1, Dollu Rakshitha ², Vurugonda sreshta ² and Kaleru Purnachander ³

Department of Pharmacy Practice, Jyothishmathi Institute of Pharmaceutical Sciences, Karimnagar, Telangana, India.
 
Review
International Journal of Science and Research Archive, 2024, 12(02), 157–161.
Article DOI: 10.30574/ijsra.2024.12.2.1175
 
Publication history: 
Received on 18 May 2024; revised on 28 June 2024; accepted on 01 July 2024
 
Abstract: 
The current treatment regiment for DS-TB(Drug Resistant Tuberculosis) was defined by 1980's since then the emergency of HIV and escalation of Drug sensitive (DS-TB)forms of TB have presented new challenges.To face these challenges, achieve goals like shortening DS -TB treatment improving DR-TB treatment and making combined TB -HIV therapy easier. A range of new drugs and treatment strategies are currently being elevated. Phase 2B and 3 clinical trials are ongoing to access combinations involving in high dose rifamycins, 8methoxyquinolines,diarylquinolines and nitroimidazoles. The new drugs advantages will contribute towards the achievement of a new treatment regimen in future. Tuberculosis according to WHO: TB is a bacterial infection that mainly affects the lungs and it is caused by the bacteria mycobacterium tuberculosis.
 
Keywords: 
Tuberculosis; Pretomanid; Delamaind; Bedaquiline.
 
Full text article in PDF: 
 
Copyright information: 

Copyright © 2024 Author(s) retain the copyright of this article. This article is published under the terms of the Creative Commons Attribution Liscense 4.0